NCT01779843View on ClinicalTrials.gov

Alisertib for Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Cytarabine

DRUG

Idarubicin

DRUG

Alisertib

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01779843 - Alisertib for Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter